WARRINGTON, Pa., July 28, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will be hosting a conference call on Wednesday, August 4, 2010, at 8:45 AM EDT. Management will provide a business update including:
  • Status of program to gain FDA approval for Surfaxin® for the prevention of RDS in premature infants 
  • Efforts to advance key pipeline programs – Surfaxin LS™ and Aerosurf®
  • Strategic alliance and financial initiatives

In addition, the Company will report financial results for the second quarter ended June 30, 2010.

Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com. The webcast is also accessible on the Internet: http://intercallus.stream57.com/DiscoveryLaboratories_080410. It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. The Internet broadcast will be available for up to 90 days after the call at both website addresses.

The call in number is 866-332-5218. The international call in number is 706-679-3237. A replay of the conference call will be available two hours after the call's completion and remain available through August 11, 2010. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 89526041.

About Discovery Labs

Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases.  Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
CONTACT:  Discovery Laboratories, Inc.          John G. Cooper, EVP and Chief Financial Officer          215-488-9300

Discovery Laboratories